Rise Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Rise Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-500	Closed	-$4.16K	–	1124
2024 Q3	$4.16K	Hold	500	–	–	﹤0.01%	1091
2024 Q2	$3.17K	Hold	500	–	–	﹤0.01%	1097
2024 Q1	$3.03K	Hold	500	–	–	﹤0.01%	1116
2023 Q4	$3.04K	Hold	500	–	–	﹤0.01%	426
2023 Q3	$2.11K	Hold	500	–	–	﹤0.01%	460
2023 Q2	$1.55K	Hold	500	–	–	﹤0.01%	543
2023 Q1	$695	Hold	500	–	–	﹤0.01%	702
2022 Q4	$995	Hold	500	–	–	﹤0.01%	650
2022 Q3	$1K	Hold	500	–	–	﹤0.01%	593
2022 Q2	$2K	Hold	500	–	–	﹤0.01%	533
2022 Q1	$2K	Hold	500	–	–	﹤0.01%	515
2021 Q4	$2.4K	Buy	+500	New	+$2.49K	﹤0.01%	508

Other funds holding AMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Rise Advisors's AMRX Position: Q4 2024 in Review

Rise Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q4 2024, closing a stake of 500 shares — an estimated $4.16K sold.

Rise Advisors first reported a position in AMRX in Q4 2021 and held it in 12 quarters. The position peaked at $4.16K in Q3 2024. 199 funds tracked by Wall St. Rank hold AMRX as of Q4 2024.

Rise Advisors reported no remaining Amneal Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Rise Advisors sold 500 Amneal Pharmaceuticals shares in Q4 2024, an estimated $4.16K.
Rise Advisors first reported a position in Amneal Pharmaceuticals in Q4 2021 and held it in 12 quarters.
Rise Advisors's Amneal Pharmaceuticals position peaked at $4.16K in Q3 2024.
199 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2024.

Based on Rise Advisors's 13F filing for Q4 2024, filed 7 Jan 2025.